Trends in net survival from prostate cancer in six European Latin countries

Pascale Grosclaude, Laurent Roche, Rafael Fuentes-Raspall, Nerea Larrañaga, GRELL EUROCARE-5 Working Group, Gemma Gatta, Milena Sant, Hade Amash, Lucia Mangone

Research output: Contribution to journalArticle

Abstract

Cancer survival is a key measure of the effectiveness of a health-care system. European Latin countries have some differences in their health system; therefore, it is of interest to compare them in terms of survival from cancer. Prostate cancer data from six countries (Belgium, France, Italy, Portugal, Spain, and Switzerland) were extracted from the EUROCARE-5 database (end of follow-up: 1 January 2009). First, the net survival (NS) was studied over the 2000-2004 period using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. Trends in NS over the 1989-2004 period and changes in the pattern of cancer excess mortality rate until 5 years after the diagnosis were examined using a multivariate excess mortality rate model. A striking increase in survival from prostate cancer occurred in European Latin countries at all ages studied. In the last period of the study, there was little difference in age-standardized NSs from prostate cancer between the six countries. The trends of the survival followed those of the incidence (except in Spain in the elderly); the increases in incidence were the highest at ages 60-70 years and, in the elderly (around 80 years), the incidence did not increase in Switzerland. The increases in NS can mainly be explained by lead-time and overdiagnosis effects. The epidemiological interpretability of the changes in prostate cancer survival in Latin countries is strongly compromised by the biases inherent to the extensive prostate-specific antigen testing.
Original languageEnglish
Pages (from-to)S114-S120
JournalEuropean Journal of Cancer Prevention
Volume26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study
DOIs
Publication statusPublished - Jan 2017

Fingerprint

Prostatic Neoplasms
Mortality
Switzerland
Spain
Incidence
Neoplasms
Portugal
Belgium
Prostate-Specific Antigen
Italy
France
Demography
Databases
Delivery of Health Care
Health

Keywords

  • Journal Article

Cite this

Grosclaude, P., Roche, L., Fuentes-Raspall, R., Larrañaga, N., Group, GRELL. EUROCARE. W., Gatta, G., ... Mangone, L. (2017). Trends in net survival from prostate cancer in six European Latin countries. European Journal of Cancer Prevention, 26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study, S114-S120. https://doi.org/10.1097/CEJ.0000000000000304

Trends in net survival from prostate cancer in six European Latin countries. / Grosclaude, Pascale; Roche, Laurent; Fuentes-Raspall, Rafael; Larrañaga, Nerea; Group, GRELL EUROCARE-5 Working; Gatta, Gemma; Sant, Milena; Amash, Hade; Mangone, Lucia.

In: European Journal of Cancer Prevention, Vol. 26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study, 01.2017, p. S114-S120.

Research output: Contribution to journalArticle

Grosclaude, P, Roche, L, Fuentes-Raspall, R, Larrañaga, N, Group, GRELLEUROCAREW, Gatta, G, Sant, M, Amash, H & Mangone, L 2017, 'Trends in net survival from prostate cancer in six European Latin countries', European Journal of Cancer Prevention, vol. 26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study, pp. S114-S120. https://doi.org/10.1097/CEJ.0000000000000304
Grosclaude P, Roche L, Fuentes-Raspall R, Larrañaga N, Group GRELLEUROCAREW, Gatta G et al. Trends in net survival from prostate cancer in six European Latin countries. European Journal of Cancer Prevention. 2017 Jan;26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study:S114-S120. https://doi.org/10.1097/CEJ.0000000000000304
Grosclaude, Pascale ; Roche, Laurent ; Fuentes-Raspall, Rafael ; Larrañaga, Nerea ; Group, GRELL EUROCARE-5 Working ; Gatta, Gemma ; Sant, Milena ; Amash, Hade ; Mangone, Lucia. / Trends in net survival from prostate cancer in six European Latin countries. In: European Journal of Cancer Prevention. 2017 ; Vol. 26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study. pp. S114-S120.
@article{450f18aae8ac4dd68c4ffb7200ca6e3f,
title = "Trends in net survival from prostate cancer in six European Latin countries",
abstract = "Cancer survival is a key measure of the effectiveness of a health-care system. European Latin countries have some differences in their health system; therefore, it is of interest to compare them in terms of survival from cancer. Prostate cancer data from six countries (Belgium, France, Italy, Portugal, Spain, and Switzerland) were extracted from the EUROCARE-5 database (end of follow-up: 1 January 2009). First, the net survival (NS) was studied over the 2000-2004 period using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. Trends in NS over the 1989-2004 period and changes in the pattern of cancer excess mortality rate until 5 years after the diagnosis were examined using a multivariate excess mortality rate model. A striking increase in survival from prostate cancer occurred in European Latin countries at all ages studied. In the last period of the study, there was little difference in age-standardized NSs from prostate cancer between the six countries. The trends of the survival followed those of the incidence (except in Spain in the elderly); the increases in incidence were the highest at ages 60-70 years and, in the elderly (around 80 years), the incidence did not increase in Switzerland. The increases in NS can mainly be explained by lead-time and overdiagnosis effects. The epidemiological interpretability of the changes in prostate cancer survival in Latin countries is strongly compromised by the biases inherent to the extensive prostate-specific antigen testing.",
keywords = "Journal Article",
author = "Pascale Grosclaude and Laurent Roche and Rafael Fuentes-Raspall and Nerea Larra{\~n}aga and Group, {GRELL EUROCARE-5 Working} and Gemma Gatta and Milena Sant and Hade Amash and Lucia Mangone",
year = "2017",
month = "1",
doi = "10.1097/CEJ.0000000000000304",
language = "English",
volume = "26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study",
pages = "S114--S120",
journal = "European Journal of Cancer Prevention",
issn = "0959-8278",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Trends in net survival from prostate cancer in six European Latin countries

AU - Grosclaude, Pascale

AU - Roche, Laurent

AU - Fuentes-Raspall, Rafael

AU - Larrañaga, Nerea

AU - Group, GRELL EUROCARE-5 Working

AU - Gatta, Gemma

AU - Sant, Milena

AU - Amash, Hade

AU - Mangone, Lucia

PY - 2017/1

Y1 - 2017/1

N2 - Cancer survival is a key measure of the effectiveness of a health-care system. European Latin countries have some differences in their health system; therefore, it is of interest to compare them in terms of survival from cancer. Prostate cancer data from six countries (Belgium, France, Italy, Portugal, Spain, and Switzerland) were extracted from the EUROCARE-5 database (end of follow-up: 1 January 2009). First, the net survival (NS) was studied over the 2000-2004 period using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. Trends in NS over the 1989-2004 period and changes in the pattern of cancer excess mortality rate until 5 years after the diagnosis were examined using a multivariate excess mortality rate model. A striking increase in survival from prostate cancer occurred in European Latin countries at all ages studied. In the last period of the study, there was little difference in age-standardized NSs from prostate cancer between the six countries. The trends of the survival followed those of the incidence (except in Spain in the elderly); the increases in incidence were the highest at ages 60-70 years and, in the elderly (around 80 years), the incidence did not increase in Switzerland. The increases in NS can mainly be explained by lead-time and overdiagnosis effects. The epidemiological interpretability of the changes in prostate cancer survival in Latin countries is strongly compromised by the biases inherent to the extensive prostate-specific antigen testing.

AB - Cancer survival is a key measure of the effectiveness of a health-care system. European Latin countries have some differences in their health system; therefore, it is of interest to compare them in terms of survival from cancer. Prostate cancer data from six countries (Belgium, France, Italy, Portugal, Spain, and Switzerland) were extracted from the EUROCARE-5 database (end of follow-up: 1 January 2009). First, the net survival (NS) was studied over the 2000-2004 period using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. Trends in NS over the 1989-2004 period and changes in the pattern of cancer excess mortality rate until 5 years after the diagnosis were examined using a multivariate excess mortality rate model. A striking increase in survival from prostate cancer occurred in European Latin countries at all ages studied. In the last period of the study, there was little difference in age-standardized NSs from prostate cancer between the six countries. The trends of the survival followed those of the incidence (except in Spain in the elderly); the increases in incidence were the highest at ages 60-70 years and, in the elderly (around 80 years), the incidence did not increase in Switzerland. The increases in NS can mainly be explained by lead-time and overdiagnosis effects. The epidemiological interpretability of the changes in prostate cancer survival in Latin countries is strongly compromised by the biases inherent to the extensive prostate-specific antigen testing.

KW - Journal Article

U2 - 10.1097/CEJ.0000000000000304

DO - 10.1097/CEJ.0000000000000304

M3 - Article

VL - 26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study

SP - S114-S120

JO - European Journal of Cancer Prevention

JF - European Journal of Cancer Prevention

SN - 0959-8278

ER -